Cargando…
The use of alpha 1 thymosin as an immunomodulator of the response against SARS-Cov2
BACKGROUND: Since the beginning of SARS-CoV2 pandemic, the mortality rate among elderly patients (60–90 years) has been around 50%, so age has been a determining factor of a worse COVID-19 prognosis. Associated with age, the thymic function involution and depletion plays an important role, that coul...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10320944/ https://www.ncbi.nlm.nih.gov/pubmed/37408063 http://dx.doi.org/10.1186/s12979-023-00351-x |
_version_ | 1785068534764666880 |
---|---|
author | Espinar-Buitrago, M. S. Tarancon-Diez, L. Vazquez-Alejo, E. Magro-Lopez, E. Genebat, M. Romero-Candau, F. Leal, M. Muñoz-Fernandez, M. A. |
author_facet | Espinar-Buitrago, M. S. Tarancon-Diez, L. Vazquez-Alejo, E. Magro-Lopez, E. Genebat, M. Romero-Candau, F. Leal, M. Muñoz-Fernandez, M. A. |
author_sort | Espinar-Buitrago, M. S. |
collection | PubMed |
description | BACKGROUND: Since the beginning of SARS-CoV2 pandemic, the mortality rate among elderly patients (60–90 years) has been around 50%, so age has been a determining factor of a worse COVID-19 prognosis. Associated with age, the thymic function involution and depletion plays an important role, that could be related to a dysregulated and ineffective innate and adaptive immune response against SARS-CoV2. Our study aims to further in vitro effect of human Thymosin-alpha-1 (α1Thy) treatment on the immune system in population groups with different thymic function levels in the scenario of SARS-CoV2 infection. RESULTS: Activation markers such as CD40, CD80 and TIM-3 were upregulated in α1Thy presence, especially in plasmacytoid dendritic cells (pDCs) and, with increased TNFα production was observed compared to untreated condition. Co-cultures of CD4 + and CD8 + T cells with DCs treated with α1Thy in response to SARS-CoV2 peptides showed a decrease in the cytokine production compared to the condition without α1Thy pre-treated. A decrease in CD40L activation co-receptor expression in CD8 + LTs was also observed, as well as an increase in PD1 in CD4 + TLs expression in both age groups. In fact, there are no age-related differences in the immunomodulatory effect of the hormone, and it seems that effector memory and terminally differentiated memory T lymphocyte subsets were the most actively influenced by the immunomodulatory α1Thy effect. Finally, the polyfunctionality measured in SARS-CoV2 Specific-T cells response was maintained in α1Thy presence in total and memory subpopulations CD4 + and CD8 + T-cells, despite decreased proinflammatory cytokines production. CONCLUSION: The hormone α1Thy could reduce, through the modulation of DCs, the amount of proinflammatory cytokines produced by T cells. Moreover, α1Thy improve lymphocyte functionality and could become a beneficial therapeutic alternative as an adjuvant in SARS-CoV2 treatment either in the acute phase after infection or reinfection. In addition, the effect on the T immune response means that α1Thy can be incorporated into the vaccination regimen, especially in the most immunologically vulnerable individuals such as the elderly. SUBJECTS: Thymosin alpha 1, Dendritic cells, SARS-CoV2-specific T cells response, Immunomodulation SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12979-023-00351-x. |
format | Online Article Text |
id | pubmed-10320944 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-103209442023-07-06 The use of alpha 1 thymosin as an immunomodulator of the response against SARS-Cov2 Espinar-Buitrago, M. S. Tarancon-Diez, L. Vazquez-Alejo, E. Magro-Lopez, E. Genebat, M. Romero-Candau, F. Leal, M. Muñoz-Fernandez, M. A. Immun Ageing Research BACKGROUND: Since the beginning of SARS-CoV2 pandemic, the mortality rate among elderly patients (60–90 years) has been around 50%, so age has been a determining factor of a worse COVID-19 prognosis. Associated with age, the thymic function involution and depletion plays an important role, that could be related to a dysregulated and ineffective innate and adaptive immune response against SARS-CoV2. Our study aims to further in vitro effect of human Thymosin-alpha-1 (α1Thy) treatment on the immune system in population groups with different thymic function levels in the scenario of SARS-CoV2 infection. RESULTS: Activation markers such as CD40, CD80 and TIM-3 were upregulated in α1Thy presence, especially in plasmacytoid dendritic cells (pDCs) and, with increased TNFα production was observed compared to untreated condition. Co-cultures of CD4 + and CD8 + T cells with DCs treated with α1Thy in response to SARS-CoV2 peptides showed a decrease in the cytokine production compared to the condition without α1Thy pre-treated. A decrease in CD40L activation co-receptor expression in CD8 + LTs was also observed, as well as an increase in PD1 in CD4 + TLs expression in both age groups. In fact, there are no age-related differences in the immunomodulatory effect of the hormone, and it seems that effector memory and terminally differentiated memory T lymphocyte subsets were the most actively influenced by the immunomodulatory α1Thy effect. Finally, the polyfunctionality measured in SARS-CoV2 Specific-T cells response was maintained in α1Thy presence in total and memory subpopulations CD4 + and CD8 + T-cells, despite decreased proinflammatory cytokines production. CONCLUSION: The hormone α1Thy could reduce, through the modulation of DCs, the amount of proinflammatory cytokines produced by T cells. Moreover, α1Thy improve lymphocyte functionality and could become a beneficial therapeutic alternative as an adjuvant in SARS-CoV2 treatment either in the acute phase after infection or reinfection. In addition, the effect on the T immune response means that α1Thy can be incorporated into the vaccination regimen, especially in the most immunologically vulnerable individuals such as the elderly. SUBJECTS: Thymosin alpha 1, Dendritic cells, SARS-CoV2-specific T cells response, Immunomodulation SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12979-023-00351-x. BioMed Central 2023-07-05 /pmc/articles/PMC10320944/ /pubmed/37408063 http://dx.doi.org/10.1186/s12979-023-00351-x Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Espinar-Buitrago, M. S. Tarancon-Diez, L. Vazquez-Alejo, E. Magro-Lopez, E. Genebat, M. Romero-Candau, F. Leal, M. Muñoz-Fernandez, M. A. The use of alpha 1 thymosin as an immunomodulator of the response against SARS-Cov2 |
title | The use of alpha 1 thymosin as an immunomodulator of the response against SARS-Cov2 |
title_full | The use of alpha 1 thymosin as an immunomodulator of the response against SARS-Cov2 |
title_fullStr | The use of alpha 1 thymosin as an immunomodulator of the response against SARS-Cov2 |
title_full_unstemmed | The use of alpha 1 thymosin as an immunomodulator of the response against SARS-Cov2 |
title_short | The use of alpha 1 thymosin as an immunomodulator of the response against SARS-Cov2 |
title_sort | use of alpha 1 thymosin as an immunomodulator of the response against sars-cov2 |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10320944/ https://www.ncbi.nlm.nih.gov/pubmed/37408063 http://dx.doi.org/10.1186/s12979-023-00351-x |
work_keys_str_mv | AT espinarbuitragoms theuseofalpha1thymosinasanimmunomodulatoroftheresponseagainstsarscov2 AT tarancondiezl theuseofalpha1thymosinasanimmunomodulatoroftheresponseagainstsarscov2 AT vazquezalejoe theuseofalpha1thymosinasanimmunomodulatoroftheresponseagainstsarscov2 AT magrolopeze theuseofalpha1thymosinasanimmunomodulatoroftheresponseagainstsarscov2 AT genebatm theuseofalpha1thymosinasanimmunomodulatoroftheresponseagainstsarscov2 AT romerocandauf theuseofalpha1thymosinasanimmunomodulatoroftheresponseagainstsarscov2 AT lealm theuseofalpha1thymosinasanimmunomodulatoroftheresponseagainstsarscov2 AT munozfernandezma theuseofalpha1thymosinasanimmunomodulatoroftheresponseagainstsarscov2 AT espinarbuitragoms useofalpha1thymosinasanimmunomodulatoroftheresponseagainstsarscov2 AT tarancondiezl useofalpha1thymosinasanimmunomodulatoroftheresponseagainstsarscov2 AT vazquezalejoe useofalpha1thymosinasanimmunomodulatoroftheresponseagainstsarscov2 AT magrolopeze useofalpha1thymosinasanimmunomodulatoroftheresponseagainstsarscov2 AT genebatm useofalpha1thymosinasanimmunomodulatoroftheresponseagainstsarscov2 AT romerocandauf useofalpha1thymosinasanimmunomodulatoroftheresponseagainstsarscov2 AT lealm useofalpha1thymosinasanimmunomodulatoroftheresponseagainstsarscov2 AT munozfernandezma useofalpha1thymosinasanimmunomodulatoroftheresponseagainstsarscov2 |